Cited by 1,145Schizophrenia research and treatmentPharmacology and Obesity TreatmentHIV-related health complications and treatments

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2011.156

Open this paper in CoChat — free account

Abstract

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. Controversy remains about the contribution of individual antipsychotic drugs to this increased risk and whether they cause sudden cardiac death through prolongation of the corrected QT interval. Although some drug receptor-binding affinities correlate with specific cardiovascular and metabolic abnormalities, the exact pharmacological mechanisms underlying these associations remain unclear. Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both obesity-related and obesity-unrelated molecular mechanisms. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not assessed for even the most easily measurable metabolic and cardiac risk factors, such as obesity and blood pressure. Subsequently, concerns have been raised over the use of these medications, especially pronounced in vulnerable pediatric patients, among whom their use has increased markedly in the past decade and seems to have especially orexigenic effects. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and finally makes recommendations for screening and monitoring of patients taking these agents.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2011.156

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Bipolar Disorder
Yatham, L. N., & Malhi, G. S. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,515
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Systematic review and meta-analysis
Gillies, A. (2019) · CRC Press eBooks · doi:10.1201/9781315377315-19 · Cited by 2,876
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
A Population-Based Study
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,290
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975

Flagged first, then by citations

Show all 131 references

1 of the 131 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Citrome, L. Risk–benefit analysis of available treatments for schizophrenia. Psychiatric Times 1, 27–30 (2007).

Sorted by citations

Items 301–400 of 1,000

Dietary modification in the treatment of schizophrenia spectrum disorders: A systematic review
Aucoin, M., LaChance, L., Clouthier, S. N., & Cooley, K. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i8.187 · Cited by 30
Association between antipsychotic medication and clinically relevant weight change: meta-analysis
Campforts, B. C. M., Drukker, M., Crins, J., van Amelsvoort, T., & Bak, M. (2023) · BJPsych Open · doi:10.1192/bjo.2022.619 · Cited by 32
Anti-Inflammatory Effects of Peripheral Dopamine
Moore, S. C., de Castro, P. A. S. V., Yaqub, D., José, P. A., & Armando, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813816 · Cited by 32
A Naturalistic Comparison of the Long-Term Metabolic Adverse Effects of Clozapine Versus Other Antipsychotics for Patients With Psychotic Illnesses
Kelly, A. C., Sheitman, B., Hamer, R. M., Rhyne, D. C., Reed, R. M., Graham, K. A., Rau, S. W., Gilmore, J. H., Perkins, D. O., Peebles, S. S., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000159 · Cited by 32
Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review
Whitney, Z., Boyda, H. N., Procyshyn, R. M., Elbe, D., Black, T. R., Eslami, A., & Barr, A. M. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0044 · Cited by 30
Prefrontal and hippocampal brain volume deficits: role of low physical activity on brain plasticity in first-episode schizophrenia patients.
McEwen, S. C., Hardy, A., Ellingson, B. M., Jarrahi, B., Sandhu, N., Subotnik, K. L., Ventura, J., & Nuechterlein, K. H. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000983 · Cited by 29
Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study)
Lambert, M., Ruppelt, F., Siem, A.-K., Rohenkohl, A. C., Kraft, V., Luedecke, D., Sengutta, M., Schröter, R., Daubmann, A., Correll, C. U., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.036 · Cited by 29
Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India
Grover, S., Nebhinani, N., Chakrabarti, S., Avasthi, A., Kulhara, P., Basu, D., Mattoo, S. K., & Malhotra, S. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.754052 · Cited by 29
Health benefits of a physical exercise program for inpatients with mental health; a pilot study
Mazyarkin, Z., Peleg, T., Golani, I., Sharony, L., Kremer, I., & Shamir, A. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.002 · Cited by 38
Health behaviours of forensic mental health service users, in relation to smoking, alcohol consumption, dietary behaviours and physical activity—A mixed methods systematic review
Pedersen, A. L. W., Lindekilde, C. R., Andersen, K., Hjorth, P., & Gildberg, F. A. (2020) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12688 · Cited by 30
Cardiometabolic Risk in First Episode Psychosis Patients
Smith, J., Griffiths, L., Band, M., & Horne, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.564240 · Cited by 29
Mechanism and treatments of antipsychotic-induced weight gain
Ye, W., Xing, J., Yu, Z., Hu, X., & Yan, Z. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01291-8 · Cited by 34
Mechanisms of action of brain insulin against neurodegenerative diseases
Ramalingam, M., & Kim, S. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1147-1 · Cited by 30
CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia
Yu, W., Binder, M. D., Moons, T., Claes, S. J., Correll, C. U., & van Winkel, R. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318283925e · Cited by 29
Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia
Zhao, M., Qin, B., Wang, J., Zhang, Y., Zhao, J., Mao, Y., Zhang, X., & Zhang, R. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000834 · Cited by 29
Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia
Attar, R., Wester, A., Koul, S. M., Eggert, S., Polcwiartek, C., Jernberg, T., Erlinge, D., & Andell, P. (2020) · Open Heart · doi:10.1136/openhrt-2020-001286 · Cited by 28
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
Correll, C. U., Højlund, M., Graham, C. E., Todtenkopf, M. S., McDonnell, D., & Simmons, A. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad029 · Cited by 30
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole
Potkin, S. G., Raoufinia, A., Mallikaarjun, S., Bricmont, P., Peters-Strickland, T. S., Kasper, W., Baker, R. A., Eramo, A., Sanchez, R., & McQuade, R. D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.821973 · Cited by 28
Improving the physical health of people with severe mental illness in a low secure forensic unit: An uncontrolled evaluation study of staff training and physical health care plans
Haddad, M., Llewellyn‐Jones, S., Yarnold, S., & Simpson, A. (2016) · International Journal of Mental Health Nursing · doi:10.1111/inm.12246 · Cited by 28
Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder
Lambert, M., Niehaus, V., & Correll, C. U. (2016) · Pharmacopsychiatry · doi:10.1055/s-0042-116668 · Cited by 28
Brain insulin action: Implications for the treatment of schizophrenia
Agarwal, S. M., Kowalchuk, C., Castellani, L. N., Costa-Dookhan, K. A., Caravaggio, F., Asgariroozbehani, R., Chintoh, A. F., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.032 · Cited by 30
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
Yagoda, S., Graham, C. E., Simmons, A., Arevalo, C., Jiang, Y., & McDonnell, D. (2020) · CNS Spectrums · doi:10.1017/s1092852920001376 · Cited by 28
Association of family history of schizophrenia and clinical outcomes in individuals with eating disorders
Zhang, R., Kuja‐Halkola, R., Birgegård, A., Larsson, H., Lichtenstein, P., Bulik, C. M., & Bergen, S. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721001574 · Cited by 28
Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
Edinoff, A. N., Ellis, E. D., Nussdorf, L., Hill, T. W., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14010024 · Cited by 31
Examining Nutrition Knowledge, Skills, and Eating Behaviours in People with Severe Mental Illness: A Cross-Sectional Comparison among Psychiatric Inpatients, Outpatients, and Healthy Adults
Mötteli, S., Provaznikova, B., Vetter, S., Jäger, M., Seifritz, E., & Hotzy, F. (2023) · Nutrients · doi:10.3390/nu15092136 · Cited by 28
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders
Moteshafi, H., Zhornitsky, S., Brunelle, S., & Stip, É. (2012) · Drug Safety · doi:10.1007/bf03261978 · Cited by 28
Metabolic syndrome and diabetes mellitus in COPD
Wells, C. E., & Baker, E. H. (2013) · European Respiratory Society eBooks · doi:10.1183/1025448x.10011912 · Cited by 28
TAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial
Stürup, A. E., Jensen, H., Dolmer, S., Birk, M., Albert, N., Nielsen, M., Hjorthøj, C. R., Eplov, L. F., Ebdrup, B. H., Mors, O. N., et al. (2017) · Trials · doi:10.1186/s13063-017-2172-4 · Cited by 31
Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents
Carnovale, C., Battini, V., Santoro, C., Riccio, M. P., Carucci, S., Nobile, M., Formisano, P., Bravaccio, C., Zuddas, A., Clementi, E., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2023.04.018 · Cited by 27
Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia
Chalfoun, C., Karelis, A. D., Stip, É., & Abdel‐Baki, A. (2015) · Journal of Sports Sciences · doi:10.1080/02640414.2015.1119875 · Cited by 29
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial
Jensen, K. G., Correll, C. U., Rudå, D., Klauber, D. G., Decara, M. S., Fagerlund, B., Jepsen, J. R. M., Eriksson, F., Fink‐Jensen, A., & Pagsberg, A. K. (2019) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.01.015 · Cited by 27
Mortality Risk of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia
Yeh, T., Tzeng, N., Li, J., Huang, Y., Hsieh, H.-T., Chu, C., & Liang, C. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001083 · Cited by 27
Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review
Misera, A., Łoniewski, I., Palma, J., Kulaszyńska, M., Czarnecka, W., Kaczmarczyk, M., Liśkiewicz, P., Samochowiec, J., & Skonieczna‐Żydecka, K. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1125022 · Cited by 28
Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats
Liu, X., Deng, C., Cao, S., Gong, J., Wang, B., & Hu, C. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.033 · Cited by 27
Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy
Burghardt, K. J., & Ellingrod, V. L. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0017-8 · Cited by 27
Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum
Andreazza, A. C., Barakauskas, V., Fazeli, S., Feresten, A. H., Shao, L., Wei, V., Wu, C. H., Barr, A. M., & Beasley, C. L. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.02.028 · Cited by 27
Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients
Rasmussen, H., Ebdrup, B. H., Oranje, B., Pinborg, L. H., Knudsen, G. M., & Glenthoj, B. Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000777 · Cited by 27
A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
Bodén, R., Edman, Reutfors, J., Östenson, C., & Ösby (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40554 · Cited by 27
Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study
Nielsen, R. E., Laursen, M. F., Vernal, D. L., Bisgaard, C., Jakobsen, H. N., Steinhausen, H., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.04.023 · Cited by 29
Patterns of psychotropic medication use in inpatient and outpatient psychiatric settings in Saudi Arabia
Alhabbad, A. A., Alosaimi, F. D., Abalhassan, M. F., Fallata, E. O., Alzain, N. M., Alassiry, M. Z., & Haddad, B. A. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s100405 · Cited by 27
Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review
van der Burg, K. P., Cribb, L., Firth, J., Karmacoska, D., & Sarris, J. J. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1625222 · Cited by 28
Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity
Heal, D. J., Gosden, J., Jackson, H. C., Cheetham, S. C., & Smith, S. L. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_6 · Cited by 27
Psychopharmacologic Treatment of Psychosis in Children and Adolescents
Kranzler, H. N., & Cohen, S. D. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.06.002 · Cited by 28
Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm
Cohen, D., & Binder, M. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.94 · Cited by 27
Metabolic effects of atypical antipsychotics: Molecular targets
Fonseca, M., Carmo, F., & Martel, F. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13347 · Cited by 26
IUPHAR themed review: The gut microbiome in schizophrenia
Kamath, S., Sokolenko, E., Collins, K., Chan, N. S. L., Mills, N. T., Clark, S. R., Marques, F. Z., & Joyce, P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107561 · Cited by 26
Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
Kishi, T., Ikuta, T., Matsunaga, S., Matsuda, Y., Oya, K., & Iwata, N. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s134340 · Cited by 26
Clozapine-Associated Aspiration Pneumonia: Case Series and Review of the Literature
Kaplan, J., Schwartz, A. C., & Ward, M. C. (2017) · Psychosomatics · doi:10.1016/j.psym.2017.08.011 · Cited by 26
Disordered eating behaviors as a potential obesogenic factor in schizophrenia
Kouidrat, Y., Amad, A., Stubbs, B., Louhou, R., Renard, N., Diouf, M., Lalau, J., & Loas, G. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.083 · Cited by 26
Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes
Joseph, J., & Law, C. A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.010 · Cited by 26
Improving the physical health of people with severe mental illness
Silverwood, V., Chew-Graham, C. A., & Shiers, D. (2019) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738018823800 · Cited by 26
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients
Vázquez-Bourgón, J., Alario, M. I., Son, J. M.-V., Gómez‐Revuelta, M., Ayesa‐Arriola, R., Ruiz, M. J., de la Foz, V. O., & Crespo‐Facorro, B. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.009 · Cited by 26
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Le, G. H., Gillissie, E. S., Rhee, T. G., Cao, B., Alnefeesi, Y., Guo, Z., Vincenzo, J. D. D., Jawad, M. Y., March, A. M., Ramachandra, R., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2206559 · Cited by 26
Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis
Galling, B., Garcia, M. A., Osuchukwu, U., Hagi, K., & Correll, C. U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1053457 · Cited by 26
Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation
Grossini, E., Gramaglia, C. M., Farruggio, S., Bellofatto, K., Anchisi, C., Mary, D., Vacca, G., & Zeppegno, P. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.01.008 · Cited by 26
Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders
Gohar, S. M., Dieset, I., Steen, N. E., Mørch, R. H., Iversen, T., Steen, V. M., Andreassen, O. A., & Melle, I. S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0897-z · Cited by 28
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
Carmellini, P., Cuomo, A., Rescalli, M. B., & Fagiolini, A. M. (2025) · Life · doi:10.3390/life15091422 · Cited by 27
Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment
Zhai, D., Cui, T., Xu, Y., Feng, Y., Wang, X., Yang, Y., Li, S., Zhou, D., Dong, G., Zhao, Y., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.09.001 · Cited by 25
The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study
Kokras, N., Papadopoulou, E., Georgiopoulos, G. A., Dalla, C., Petropoulos, Ι., Kontogiannis, C., Laina, A., Bampatsias, D., Stellos, K., Kouzoupis, A. V., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.024 · Cited by 26
Early Intervention in Psychosis: Effectiveness and Implementation of a Combined Exercise and Health Behavior Intervention Within Routine Care
Smith, J., Griffiths, L., Band, M., Hird-Smith, R., Williams, B., Bold, J., Bradley, E., Dilworth, R., & Horne, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.577691 · Cited by 24
Antipsychotic-induced bone loss: the role of dopamine, serotonin and adrenergic receptor signalling
Weerasinghe, D. K., Hodge, J. M., Pasco, J. A., Samarasinghe, R. M., Manavi, B. A., & Williams, L. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1184550 · Cited by 28
The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects
Wang, H. R., Woo, Y. S., & Bahk, W. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000135 · Cited by 25
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia
Delacrétaz, A., Vandenberghe, F., Gholam‐Rezaee, M., Saigí-Morgui, N., Glatard, A., Thonney, J., Solida-Tozzi, A., Kolly, S., Gallo, S. F., Baumann, P., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.002 · Cited by 27
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances
Inoue, Y., Tsuchimori, K., & Nakamura, H. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.09.006 · Cited by 25
Automated Assessment of Psychiatric Disorders Using Speech: A Systematic ReviewPreprint
Low, D. M., Bentley, K. H., & Ghosh, S. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/5pwze · Cited by 30
Can prebiotics assist in the management of cognition and weight gain in schizophrenia?
Kao, A. C.-C., Burnet, P. W. J., & Lennox, B. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.027 · Cited by 24
Second-generation antipsychotics induce cardiotoxicity by disrupting spliceosome signaling: Implications from proteomic and transcriptomic analyses
Wang, J., Li, X., Liu, Z., Lin, X., Zhong, F., Li, S., Tang, X., Zhang, Y., & Li, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105714 · Cited by 24
Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality
Berge, J., Abri, P., Andell, P., Movahed, P., & Ragazan, D. C. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.11.023 · Cited by 24
Metformin for the prevention of clozapine‐induced weight gain: A retrospective naturalistic cohort study
Stogios, N., Maksyutynska, K., Navagnanavel, J., Sanches, M., Powell, V., Gerretsen, P., Graff‐Guerrero, A., Chintoh, A. F., Foussias, G., Remington, G. J., et al. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13462 · Cited by 26
Current progress in understanding schizophrenia using genomics and pluripotent stem cells: A meta-analytical overview
Choudhary, A., Peles, D., Nayak, R., Mizrahi, L., & Stern, S. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.11.001 · Cited by 21
Metabolic and Cardiovascular Adverse Effects Associated with Treatment with Antipsychotic Drugs
Chang, S.-C., & Lu, M. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.01.007 · Cited by 24
Who is responsible for metabolic screening for mental health clients taking antipsychotic medications?
Ward, T., Wynaden, D., & Heslop, K. (2017) · International Journal of Mental Health Nursing · doi:10.1111/inm.12309 · Cited by 24
Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
Paderina, D. Z., Boiko, A. S., Pozhidaev, I. V., Бочарова, А. В., Mednova, I. A., Fedorenko, O. Y., Kornetova, E. G., LOONEN, A. J. M., Semke, A. V., Bokhan, N. A., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030181 · Cited by 24
Exercise as a Therapeutic Intervention for Chronic Disease Management: A Comprehensive Review
Fairag, M., Alzahrani, S. A., Alshehri, N., Alamoudi, A. O., Alkheriji, Y., Alzahrani, O. A., Alomari, A. J., Alzahrani, Y., Alghamdi, S. M., & Fayraq, A. (2024) · Cureus · doi:10.7759/cureus.74165 · Cited by 25
Excess cardiometabolic risk in children and adolescents initiating antipsychotic treatment compared to young adults: results from a nationwide cohort study
Højlund, M., Wesselhoeft, R. T., Heinrichsen, M., Pagsberg, A. K., Correll, C. U., & Steinhausen, H. (2025) · World Psychiatry · doi:10.1002/wps.21279 · Cited by 23
No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder
Vo, L. C., Snyder, C. S., McCracken, C. M., McDougle, C. J., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Levi, D. S., Kelleman, M. S., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0090 · Cited by 23
Interventions to Improve Metabolic Risk Screening Among Adult Patients Taking Antipsychotic Medication: A Systematic Review
Melamed, O. C., Wong, E. N., LaChance, L., Kanji, S., & Taylor, V. H. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201900108 · Cited by 28
Mortality risk of antipsychotic augmentation for adult depression
Gerhard, T., Stroup, T. S., Correll, C. U., Setoguchi, S., Strom, B. L., Huang, C., Tan, Z., Crystal, S., & Olfson, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239206 · Cited by 23
Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects
Stamoula, Ε., Ainatzoglou, A., Stamatellos, V., Dardalas, I., Siafis, S., Matsas, A., Stamoulas, K., & Papazisis, G. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103522 · Cited by 23
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Correll, C. U., Stein, E. A., Graham, C. E., DiPetrillo, L., Akerman, S. C., Stanford, A. D., Jiang, Y., Yagoda, S., McDonnell, D., & Hopkinson, C. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac144 · Cited by 23
Fatty acid transport protein-2 inhibitor Grassofermata/CB5 protects cells against lipid accumulation and toxicity
Saini, N., Black, P. N., Montefusco, D. J., & Dirusso, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.055 · Cited by 23
Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: A preliminary study.
Semız, M., Yücel, H., Kavakçı, Ö., Yıldırım, O., Zorlu, A., Yılmaz, M. B., Küçükdurmaz, Z., & Canan, F. (2013) · Europe PMC (PubMed Central) · Cited by 23
Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 23
Direct and indirect effects of psychopharmacological treatment on the cardiovascular system
Kahl, K. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0054 · Cited by 23
Motivational theory-based interventions on health of people with several mental illness: A systematic review and meta-analysis
Romain, A. J., Bernard, P., Akrass, Z., St‐Amour, S., Lachance, J.-P., Hains-Monfette, G., Atoui, S., Kingsbury, C., Dubois, È., Karelis, A. D., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.049 · Cited by 27
Investigation of the protective effect of resveratrol in an MK-801-induced mouse model of schizophrenia
AKOSMAN, M. S., Türkmen, R., & Demirel, H. H. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15664-x · Cited by 23
Liver Illness and Psychiatric Patients
Carrier, P., Debette‐Gratien, M., Girard, M. F., Jacques, J., Nubukpo, P., & Loustaud-Ratti, V. (2016) · Hepatitis Monthly · doi:10.5812/hepatmon.41564 · Cited by 25
GLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future
Trott, M., Arnautovska, U., & Siskind, D. J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000952 · Cited by 23
Homocysteine level, body mass index and clinical correlates in Chinese Han patients with schizophrenia
Huang, Y., Wu, K., Li, H., Zhou, J., Xiong, D., Huang, X., Li, J., Liu, Y., Pan, Z., Mitchell, D. T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72934-3 · Cited by 22
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study
Filts, Y., Litman, R. E., Martínez, J., Anta, L., Naber, D., & Correll, C. U. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.11.030 · Cited by 24
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
Schoretsanitis, G., Dubath, C., Grosu, C., Piras, M., Laaboub, N., Ranjbar, S., Ansermot, N., Crettol, S., Vandenberghe, F., Gamma, F., et al. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13715 · Cited by 22
Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression
Zhang, T., Guo, L., Li, R., Wang, F., Yang, W., Yang, J.-B., Cui, Z.-Q., Zhou, C., Chen, Y., Yu, H., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.927817 · Cited by 23
Antipsychotic-Induced Alterations in Lipid Turnover
Pereira, S., Au, E., Agarwal, S. M., Wright, D. C., & Hahn, M. (2023) · Endocrinology · doi:10.1210/endocr/bqad025 · Cited by 23
Myocarditis in patients on long-term antipsychotics –mechanism, management and recent updates
Daniel, P., Katta, M. R., Luna, R., Sadeque, J., Prasad, S., Avanthika, C., & Jhaveri, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13930 · Cited by 24
Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone
Manu, P., Correll, C. U., Wampers, M., van Winkel, R., Yu, W., Shiffeldrim, D., Kane, J. M., & Binder, M. D. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.11.016 · Cited by 23
Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods
Reeves, G. M., Keeton, C. P., Correll, C. U., Johnson, J. L., Hamer, R. M., Sikich, L., Hazzard, L. M., Alderman, C., Scheer, A., Mabe, M., et al. (2013) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-7-31 · Cited by 23
10-year CVD risk in Han Chinese mainland patients with schizophrenia
Zhao, S., Xia, H., Mu, J., Wang, L., Zhu, L., Wang, A., & Zhou, X. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.020 · Cited by 22
Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids
Manzo, C., Mestres, J. S., Castagna, A., & Isetta, M. (2018) · Medicines · doi:10.3390/medicines5030082 · Cited by 22
Willingness to use smartphone apps for lifestyle management among patients with schizophrenia
Lee, K., Bejerano, I. L., Han, M., & Choi, H. (2019) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2019.01.002 · Cited by 22
Advances in clinical staging, early intervention, and the prevention of psychosis
Gupta, T., & Mittal, V. A. (2019) · F1000Research · doi:10.12688/f1000research.20346.1 · Cited by 22

Authors: De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U.
Affiliations: KU Leuven (BE)
Zucker Hillside Hospital (US)
ORCID: Detraux, Johan
Correll, Christoph U.
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-18
Volume: 8
Issue: 2
Pages: 114-126
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2011.156
OpenAlex: W2014026290
Cited by: 1,145
References: 131
Citations by year: 2026: 85 · 2025: 75 · 2024: 62 · 2023: 91 · 2022: 97 · 2021: 99 · 2020: 84 · 2019: 77 · 2018: 73 · 2017: 85 · 2016: 74 · 2015: 75 · 2014: 65 · 2013: 52 · 2012: 44
FWCI: 6.96
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: antipsychotic drugs, type 2 diabetes, cardiovascular disease, metabolic side effects, obesity, hyperglycemia, dyslipidemia, metabolic syndrome, QT prolongation, sudden cardiac death, glucose metabolism, lipid metabolism, health care disparities, screening and monitoring
MeSH terms: Adult, Cardiovascular Diseases, Child, Diabetes Mellitus, Humans, Metabolic Diseases, Antipsychotic Agents, Weight Gain, Death, Sudden, Cardiac

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks